Related Experiment Videos
[Focus on beta-blockers for vascular specialists in 2012]
S Mairesse1, J Blacher, M-E Safar
1Unité d'Hypertension Artérielle, Prévention et Thérapeutique Cardiovasculaires, Centre de Diagnostic et de Thérapeutique, Université Paris-Descartes, Hôtel-Dieu, AP-HP, place du Parvis-Notre-Dame, 75004 Paris, France.
Journal Des Maladies Vasculaires
|November 19, 2011
Summary
Beta-blockers effectively reduce mortality in heart attack and heart failure patients. However, their use in hypertension is debated due to potential increased cardiovascular risks, necessitating further research.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers, available since 1964, have established cardiovascular benefits.
- Numerous studies confirm their efficacy in reducing mortality for various cardiovascular conditions.
Purpose of the Study:
- To review the established and debated indications for beta-blockers in cardiovascular diseases.
- To assess the current evidence regarding beta-blockers in hypertension, post-infarction care, heart failure, and perioperative settings.
Main Methods:
- Review of existing literature, meta-analyses, and clinical guidelines.
- Analysis of study outcomes concerning mortality, cardiovascular events, and blood pressure control.
Main Results:
- Beta-blockers reduce mortality in post-infarction, acute coronary syndrome, and heart failure patients.
- While recommended for rate control in atrial fibrillation, their first-line use in hypertension is questioned due to potential increased risks.
- Perioperative use shows disappointing results, and peripheral artery disease may favor their prescription.
Conclusions:
- Beta-blockers remain crucial for heart failure and post-infarction care.
- Further research on central blood pressure effects is needed to clarify their role in hypertension management.
- Their utility in other vascular conditions requires careful consideration.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...